ContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL Pharmaceutical Investing
Elite Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2018 Pharmaceutical Investing
Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration Pharmaceutical Investing
Catalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB Biotech Investing
Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update Biotech Investing
Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA Pharmaceutical Investing
Onconova Therapeutics Announces Pricing of $8.7 Million Underwritten Public Offering Biotech Investing
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
